Proteins are essential to every cell in the body and when dysregulated, can play a role in activating disease-driving cellular pathways. Utilizing the team’s deep scientific expertise, Kezar is developing novel, first-in-class, small molecule approaches for targeting select proteins to regulate cellular function.

Zetomipzomib (KZR-616) is a first-in-class, selective immunoproteasome inhibitor for a range of autoimmune diseases. Immunoproteasomes play an important role in regulating the normal function of the immune system and when inhibited, multiple pathways involved in inflammatory cytokine production and immune effector cell activity – including macrophages, B cells and T …

4000 Shoreline Court Suite 300 South San Francisco, CA 94080. [email protected] (650) 822-5600. Visit us on LinkedIn

At Kezar Life Sciences, we are developing first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins.

John Fowler is our Co-Founder and a member of the board of directors. He served as Chief Executive Officer of Kezar from June 2015 to November 2023. Prior to Kezar, between 2009 and 2014 John co-founded and was CEO of HealthCPA, a provider of patient advocacy and insurance navigation services.

Unlike other therapeutic options that target a single type of immune cell or cytokine, zetomipzomib (KZR-616), Kezar’s first-in-class, selective immunoproteasome inhibitor, is designed to modulate many elements of the immune system when it is dysregulated without direct immunosuppression.

Kezar Life Sciences is committed to developing safe and effective therapies for serious diseases that impact patients and their families. To achieve this, we conduct clinical trials to assess the risks and benefits of our investigational therapies.

%PDF-1.6 %âãÏÓ 1352 0 obj > endobj 1397 0 obj >/Filter/FlateDecode/ID[839B5D630F14634D9CF813FEA09A8170>014E19398181494588915DDFF93CBF47>]/Index[1352 95]/Info 1351 ...

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 4, 2024-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was informed via

Department of Research, Kezar Life Sciences, South San Francisco, CA, United States Zetomipzomib (KZR-616) is a selective inhibitor of the immunoproteasome currently undergoing clinical investigation in autoimmune disorders. Here, we characterized KZR-616 in vitro and in vivo using multiplexed cytokine analysis,